Introduction

Few corners of the London market attract attention faster than a stock flashing an extreme momentum reading, and Advanced Medical Solutions Group plc (LSE:AMS) has done exactly that, appearing among the most overbought UK shares screened by RSI. With a 14-day RSI of 74.53 — a reading above the conventional overbought threshold — AMS and the shares pushed sharply higher, last changing hands around 278.5p (+16.04% on the day). That combination is precisely what pulls traders, screeners and momentum-watchers toward the name.

So why is AMS flashing as overbought, what does that RSI signal actually mean, and what should investors weigh before assuming the rally either continues or reverses? Advanced Medical Solutions develops wound-care products and tissue adhesives sold worldwide, a profitable medical-technology business with strong cash generation. Below, we break down why Advanced Medical Solutions Group plc is in focus, how to read its overbought signal, the valuation and momentum picture, the key risks, and what could realistically support the shares from here. Crucially, an overbought reading is a description of recent price behaviour — not a forecast — and nothing here is a prediction or a recommendation.

Why AMS Stock Is in Focus

The reason AMS keeps appearing on watchlists comes down to one word — momentum. Relative strength index measures the speed and magnitude of recent price changes, and Advanced Medical Solutions Group plc's reading of 74.53 places it among the strongest movers on the entire UK market by this measure. Screens such as TradingView's 'most overbought' list specifically gather shares like this so investors can see where price changes have been quickest — and where an anticipated cooling-off or pullback might follow.

There is usually a story behind the signal as well. Momentum builds when investors collectively decide a business deserves a re-rating — on results, sector sentiment, a corporate development, or a rotation into the theme Advanced Medical Solutions Group plc sits within. As a mid-cap name with a market value of £519.37m, AMS is more heavily traded than the typical overbought micro-cap, so its appearance on the list tends to reflect genuine, broad-based buying interest rather than a handful of trades. Whatever the trigger, the RSI simply quantifies how stretched the recent move has become; it is the market's way of flagging that AMS has travelled a long way in a short time.

What an Overbought RSI May Indicate

The relative strength index, developed by J. Welles Wilder, is a momentum oscillator that runs from 0 to 100. It compares the size of recent gains to recent losses over a set period — here, 14 trading days. As a rule of thumb, a reading above 70 is considered 'overbought' and a reading below 30 'oversold'. AMS's RSI of 74.53 is therefore well into overbought territory, and a reading above the conventional overbought threshold.

A reading in this range shows the shares have been climbing steadily and have pushed beyond the level many traders treat as a caution flag. It signals strength, but also that the easy, fast part of the move may be maturing.

The critical point for investors is what overbought does and does not imply. It does not predict that AMS will fall, and it certainly does not guarantee a reversal. Strongly trending shares can remain overbought for extended periods while they keep rising — a phenomenon traders call 'staying overbought'. What an elevated RSI does flag is heightened risk of a near-term pullback, a pause, or a period of consolidation, and it suggests that anyone buying purely because a stock is rising is doing so after a large, fast move rather than before it. In other words, RSI is a measure of speed, not a verdict on the company.

Recent Market Momentum

The recent momentum behind AMS has been emphatic. The shares jumped +16.04% on the day in question, to around 278.5p, the kind of single-session move that both reflects and reinforces an overbought reading. Sharp daily gains like this typically follow a specific catalyst — a trading update, news flow, sector re-rating or a shift in sentiment — and they tend to draw in momentum buyers who amplify the move.

Momentum, of course, is a double-edged sword. The same force that carries Advanced Medical Solutions Group plc onto an overbought list can fade quickly once the buying that drove it is exhausted. Volume matters here: rallies backed by heavy, sustained turnover tend to be taken more seriously than those on light volume, which can unwind just as fast as they formed. For AMS, the question is whether the recent strength reflects a durable change in how the market values the business, or a shorter-term burst of enthusiasm that could cool. RSI cannot answer that question — only the underlying fundamentals and future news flow can.

Valuation and Investor Concerns

Advanced Medical Solutions Group plc trades on a trailing price-to-earnings (P/E) multiple of about 61.62, with diluted earnings of £0.05 per share. That is a punchy rating that prices in continued growth, and it is part of why the stock draws 'overvalued' labels: after a strong run, the shares are valued at a meaningful premium to the broader market, leaving less room for disappointment.

The investor concern that flows from all of this is straightforward. After a fast advance, the gap between price and what the fundamentals currently justify can widen, and that is exactly what 'most overvalued' or 'most overbought' lists are designed to highlight. For Advanced Medical Solutions Group plc, the practical takeaway is not that the shares are doomed to fall — momentum can persist — but that buyers at these levels are paying up after the move, and the margin for error is thinner than it was before the rally. A useful discipline is to separate the quality of the business from the price being asked for it today.

Key Risks to Watch

Set against the bullish momentum, there are several risks investors should keep firmly in view for AMS:

• A one-day jump of around 16% that may reflect a specific event

• A very high trailing earnings multiple

• Regulatory and product-approval risk

• The mechanical risk that an overbought RSI is followed by a pullback or period of consolidation

• The chance that momentum buyers exit as quickly as they arrived if news flow disappoints

Taken together, these factors explain why technical screens flag names like AMS as ones to handle with care. None of them means a decline is inevitable, but each is a reason the recent pace of gains may be difficult to sustain indefinitely. Risk-aware investors typically pay particular attention to liquidity and position size in shares that have moved this far this fast, because the same thinness that can accelerate a rise can accelerate a fall.

What Could Support the Stock

On the other side of the ledger, several factors could underpin AMS even after its strong run:

• A differentiated medical-technology portfolio

• Global distribution and strong margins

• Cash generation and a robust balance sheet

If these supports prove durable, the market may continue to award Advanced Medical Solutions Group plc a higher rating, and an elevated RSI can persist for some time during a genuine re-rating. The key distinction for investors is whether the recent move is anchored in improving fundamentals — stronger earnings, structural demand, a credible strategy — or simply in price chasing price. The former can endure; the latter rarely does. As ever, this is context for your own research, not a prediction about where the shares go next.

What Investors May Watch Next for AMS

So what should investors actually monitor from here? Several things stand out for AMS. First, upcoming trading updates and results, which will show whether earnings are keeping pace with the share price. Second, the behaviour of the RSI itself: whether it stays elevated (a sign momentum is intact) or rolls over and diverges from the price (often an early warning that a move is tiring). Third, trading volume — sustained turnover lends credibility to a rally, while fading volume can signal exhaustion.

Investors will also keep an eye on broader signals: sector trends affecting wound care and medical adhesives, any commentary from the company on outlook, and how the shares behave around technical levels that traders are watching. As a larger, more liquid name, AMS will also take its cue from sector sentiment and the wider market, so macro developments and peer results are worth watching alongside company-specific news. The overarching theme is simple — after a strong move, the market tends to demand evidence that the optimism is justified, and the next set of data points for Advanced Medical Solutions Group plc will be judged against high expectations.

Conclusion

In summary, Advanced Medical Solutions Group plc (AMS) has earned its place on the most overbought UK stocks list the hard way — through a fast, strong move that has driven its 14-day RSI to 74.53, a reading above the conventional overbought threshold. That signal tells you the shares have travelled a long way quickly and that the risk of a near-term pause or pullback is elevated. It does not tell you the rally is over, nor that it must continue.

With the shares on a trailing P/E of around 61.62, the valuation debate is whether the business can grow into its rating. For AMS, the sensible posture is to treat the overbought reading as one input among many: a prompt to look harder at the fundamentals, the liquidity, and the catalysts behind the move, rather than as a buy or sell trigger in its own right. Whether Advanced Medical Solutions Group plc's momentum proves durable or fades will ultimately be decided by results, news flow and market sentiment — not by the RSI alone. Investors should do their own research and, where needed, seek professional advice suited to their circumstances.